Hiroki Hara

15.3k total citations · 4 hit papers
232 papers, 4.4k citations indexed

About

Hiroki Hara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Hiroki Hara has authored 232 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Oncology, 115 papers in Pulmonary and Respiratory Medicine and 99 papers in Surgery. Recurrent topics in Hiroki Hara's work include Gastric Cancer Management and Outcomes (92 papers), Colorectal Cancer Treatments and Studies (63 papers) and Esophageal Cancer Research and Treatment (60 papers). Hiroki Hara is often cited by papers focused on Gastric Cancer Management and Outcomes (92 papers), Colorectal Cancer Treatments and Studies (63 papers) and Esophageal Cancer Research and Treatment (60 papers). Hiroki Hara collaborates with scholars based in Japan, United States and South Korea. Hiroki Hara's co-authors include Ken Kato, Takashi Kojima, Mitsunobu Sato, Kei Muro, Kensei Yamaguchi, Kohei Shitara, Yasuo Hamamoto, Yuko Kitagawa, Shuichi Hironaka and Masako Asayama and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Hiroki Hara

215 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

2020 567 citations Hiroki Hara, Takashi Kojima et al. Journal of Clinical Oncology profile →
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

2017 292 citations Toshihiro Kudo, Yasuo Hamamoto et al. profile →
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

2018 228 citations Narikazu Boku, Ken Kato et al. Annals of Oncology profile →
A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.

2022 119 citations Ken Kato, Yoshinori Ito et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hiroki Hara Japan	34	2.3k	2.0k	1.9k	462	455	232	4.4k
Yasuo Hamamoto Japan	33	2.9k 1.2×	3.3k 1.7×	3.0k 1.6×	738 1.6×	298 0.7×	155	5.8k
Felipe A. Calvo Spain	31	2.9k 1.2×	2.2k 1.1×	2.3k 1.2×	313 0.7×	224 0.5×	266	5.3k
Susan C. Abraham United States	56	2.1k 0.9×	2.2k 1.1×	4.0k 2.2×	1.1k 2.4×	1.2k 2.6×	192	8.6k
Akio Yamaguchi Japan	37	1.3k 0.6×	746 0.4×	974 0.5×	252 0.5×	495 1.1×	242	4.4k
Johannes J. Bonenkamp Netherlands	28	1.2k 0.5×	4.0k 2.0×	2.2k 1.2×	2.2k 4.7×	149 0.3×	65	5.7k
Hyo‐Cheol Kim South Korea	40	440 0.2×	1.5k 0.8×	2.3k 1.2×	381 0.8×	290 0.6×	261	5.9k
Yanling Ma United States	28	762 0.3×	766 0.4×	909 0.5×	326 0.7×	139 0.3×	100	2.7k
Christopher J. Schultz United States	37	2.0k 0.8×	3.0k 1.5×	2.4k 1.3×	73 0.2×	1.4k 3.0×	138	8.7k
David Chang United States	40	780 0.3×	1.3k 0.6×	3.8k 2.0×	106 0.2×	165 0.4×	140	6.3k
Vani J. Konda United States	32	1.3k 0.6×	1.8k 0.9×	2.4k 1.3×	822 1.8×	85 0.2×	160	3.9k

Countries citing papers authored by Hiroki Hara

Since Specialization

Citations

This map shows the geographic impact of Hiroki Hara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroki Hara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroki Hara more than expected).

Fields of papers citing papers by Hiroki Hara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroki Hara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroki Hara. The network helps show where Hiroki Hara may publish in the future.

Co-authorship network of co-authors of Hiroki Hara

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroki Hara. A scholar is included among the top collaborators of Hiroki Hara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroki Hara. Hiroki Hara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kawakami, Hisato, Shigenori Kadowaki, Akitaka Makiyama, et al.. (2025). Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer. Journal of Clinical Oncology. 43(19). 2184–2195. 2 indexed citations

Sakai, Daisuke, Shigenori Kadowaki, Ryohei Kawabata, et al.. (2025). Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial. Journal of Clinical Oncology. 43(19). 2196–2207. 3 indexed citations

Du, Wenting, Xi Jiao, Yanni Wang, et al.. (2025). NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial. Journal of Clinical Oncology. 43(16). 1898–1909. 2 indexed citations

Shitara, Kohei, Motohiro Tamiya, Kyoichi Okishio, et al.. (2025). Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study. Cancer Research Communications. 5(10). 1809–1820.

Sugawara, Kotaro, Takashi Fukuda, Chiaki Murakami, et al.. (2024). Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma. Cancer Science. 115(8). 2819–2830. 5 indexed citations

Muro, Kei, Keisho Chìn, Steven B. Maron, et al.. (2024). Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202.. Journal of Clinical Oncology. 42(16_suppl). 4046–4046. 2 indexed citations

Fujiwara, Yutaka, Yasutoshi Kuboki, Masayuki Furukawa, et al.. (2023). FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies. Cancer Medicine. 12(9). 10597–10611. 7 indexed citations

Muro, Kei, Hisato Kawakami, Shigenori Kadowaki, et al.. (2023). 1513MO A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7). Annals of Oncology. 34. S852–S853. 10 indexed citations

Kajiwara, Takeshi, Tomohiro Nishina, Yoshiaki Nakamura, et al.. (2023). Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Cancers. 15(21). 5172–5172. 1 indexed citations

10.

Kawazoe, Akihito, Kensei Yamaguchi, Tsuyoshi Hamaguchi, et al.. (2023). 1546P Safety, efficacy, and biomarkers for ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal cancer. Annals of Oncology. 34. S867–S867. 1 indexed citations

11.

Kojima, Takashi, Ken Kato, Hiroki Hara, et al.. (2022). Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303). Esophagus. 19(4). 702–710. 17 indexed citations

12.

Kawakami, Hisato, Shuichi Hironaka, Taito Esaki, et al.. (2021). An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers. 13(4). 805–805. 14 indexed citations

13.

Lin, Chia‐Chi, Toshihiko Doi, Kei Muro, et al.. (2021). Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. Targeted Oncology. 16(4). 447–459. 22 indexed citations

14.

Mizukami, Takuro, Tempei Miyaji, Yukiya Narita, et al.. (2021). An Observational Study on Nutrition Status in Gastric Cancer Patients Receiving Ramucirumab Plus Taxane: BALAST Study. Future Oncology. 17(19). 2431–2438. 2 indexed citations

15.

Kato, Ken, Yuichiro� Doki, Takashi Ura, et al.. (2020). Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. Cancer Science. 111(5). 1676–1684. 23 indexed citations

16.

Hironaka, Shuichi, Azusa Komori, Ryunosuke Machida, et al.. (2020). The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909. Esophagus. 17(4). 417–424. 8 indexed citations

17.

Yamamoto, Shun, Ken Kato, Hiroyuki Daiko, et al.. (2020). Feasibility Study of Nivolumab as Neoadjuvant Chemotherapy for Locally Esophageal Carcinoma: FRONTiER (JCOG1804E). Future Oncology. 16(19). 1351–1357. 44 indexed citations

18.

Kobayashi, Satoshi, Makoto Ueno, Hiroki Hara, et al.. (2016). Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer. Oncology. 91(3). 117–126. 2 indexed citations

19.

Takatori, Kazumasa, et al.. (2013). The influence of aliphatic amines, diamines, and amino acids on the polymorph of calcium carbonate precipitated by the introduction of carbon dioxide gas into calcium hydroxide aqueous suspensions. Journal of Crystal Growth. 386. 119–127. 55 indexed citations

20.

Hayakawa, Tohru, Kenichi Takahashi, Masao Yoshinari, et al.. (2006). Thin Carbonate Apatite Layer Deposited on Titanium using Molecular Precursor Method. 3(3). 139–146. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact